Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.
At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.
As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.
To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.
ESSENTIAL JOB FUNCTIONS:
- Responsible for leading and developing the clinical drug supply strategy, planning and management of all supply chain activities required to support global Phase I – III clinical studies including forecasting, supply planning, IRT configuration, inventory management and CMO management
- Collaborate with the Clinical Development and Clinical Operations teams from protocol development through final study design to have an in-depth understanding of the clinical study requirements and assumptions needed to set up the supply chain required to support the execution of the study and develop the IP forecast
- Participate in Clinical Sub Team (CST) meetings, Study Team meetings, Project Team meetings and present Supply Chain updates as required to the Kura cross-functional team
- Develop an expert-level understanding of the IRT system used to manage site activation, IP site shipments, monitor patient enrollment, patient visits, determine trends and execute adjustments
- Manage extensive internal and external touchpoints and maintain close communication and collaboration to ensure adequate clinical drug supply for multiple global clinical trials while ensuring compliance with cGMP and global regulatory requirements
- Responsible for providing commercial supply chain support in collaboration with the Manufacturing, Quality and the Commercial team including serialization expertise, as well as the release and distribution of commercial product from 3PL to authorized trading partners in compliance with the Drug Supply Chain Security Act (DSCSA)
- Participate in the creation and maintenance of clinical and commercial SOP’s and Work Instructions and related documentation
- Lead continuous improvement initiatives in collaboration with the IMSC team, as well as cross-functional partners to document, standardize and streamline core supply chain processes supporting Kura’s clinical programs, as well as the commercial supply chain
- Support financial planning for global clinical studies including budgeting, forecasting and strategic planning activities
Job Specifications:
- Technical degree or equivalent (BS/MS), preferably in Supply Chain or IT
- 8-10 years pharmaceutical/biotechnology supply chain planning and forecasting experience, preferably in a manufacturing or commercial environment
- 3- 5 years of leadership experience in pharmaceutical/biotechnology industry with a proven track record of leading teams and delivering results
- Experience managing complex global supply chain operations including vendor partnerships, contract negotiations, while ensuring compliance with cGMP regulations and requirements
- Experience collaborating with Manufacturing, Quality and CMO’s including providing a 12 – 24 month rolling forecast of drug product requirements, managing production schedules and coordinating FG deliveries
- Comprehensive knowledge of CMC requirement/activities including development, validation, regulatory and quality requirements and timelines
The base range for a Director is $202,000 - $235,672 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.
#LI-RM1
Kura’s Values that are used for candidate selection and performance assessments:
- We work as one for patients
- We are goal-focused and deliver with excellence
- We are science-driven courageous innovators
- We strive to bring out the best in each other and ourselves
The Kura Package
- Career advancement/ development opportunities
- Competitive comp package
- Bonus
- 401K + Employer contributions
- Generous stock options
- ESPP Plan
- 20 days of PTO to start
- 18 Holidays (Including Summer & Winter Break)
- Generous Benefits Package with a variety of plans available with a substantial employer match
- Paid Paternity/Maternity Leave
- In-Office Catered lunches
- Home Office Setup
- Lifestyle Spending Stipend
- Commuter Stipend (Boston Office)
- Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (“FDA”) for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA’s acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.
Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.
If you are a California resident, please see the attached Privacy Notice CA Privacy Notice
Top Skills
Similar Jobs
What you need to know about the Boston Tech Scene
Key Facts About Boston Tech
- Number of Tech Workers: 269,000; 9.4% of overall workforce (2024 CompTIA survey)
- Major Tech Employers: Thermo Fisher Scientific, Toast, Klaviyo, HubSpot, DraftKings
- Key Industries: Artificial intelligence, biotechnology, robotics, software, aerospace
- Funding Landscape: $15.7 billion in venture capital funding in 2024 (Pitchbook)
- Notable Investors: Summit Partners, Volition Capital, Bain Capital Ventures, MassVentures, Highland Capital Partners
- Research Centers and Universities: MIT, Harvard University, Boston College, Tufts University, Boston University, Northeastern University, Smithsonian Astrophysical Observatory, National Bureau of Economic Research, Broad Institute, Lowell Center for Space Science & Technology, National Emerging Infectious Diseases Laboratories
